BIO CEO and Investor Conference to host diverse range of experts.February 2, 2012 -
From February 13-14, 2012 in NYC, 14th Annual BIO CEO and Investor Conference will feature experts representing leading clinical practitioners, investment professionals, industry analysts, and senior biotechnology executives. Plenary sessions will cover economic and business issues; Business Roundtables will focus on biotech drug launches, business models and licensing and deal making; and Therapeutic Workshops will address topics such as oncology, companion diagnostics, and diseases.
14th Annual BIO CEO & Investor Conference to Highlight 2012 Investment Outlook, New Business Models and Key Therapeutic Topics |
Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
USA
Press release date: January 31, 2012
BIO CEO & Investor Conference 2012:Biotechnology Industry Organization
WASHINGTON--The Biotechnology Industry Organization (BIO) announces plenary sessions, Business Roundtables and Therapeutic Workshops selected for the 14th Annual BIO CEO & Investor Conference. Experts chosen to speak on these panels represent leading clinical practitioners, investment professionals, industry analysts and senior biotechnology executives. The conference, to be held February 13-14, 2012 in New York City, is the largest independent investor conference focused on established and publicly-traded biotechnology companies.
"Marked by several M&A transactions, development deals and FDA approvals, 2012 has already been an eventful year in biotech. This year's program will delve into some of the therapeutic and business catalysts driving positive activity in the biopharma industry," said Alan Eisenberg, Executive Vice President, Emerging Companies & Business Development at BIO. "The regulatory and financial challenges faced by our industry highlight the need for an independent forum where top industry executives and investment professionals can convene to discuss innovative deal structures and financing mechanisms."
The BIO CEO & Investor Conference plenary sessions will cover the economic and business issues facing the biotech industry. The Business Roundtables will focus on biotech drug launches, unique business models and licensing and deal making. Therapeutic Workshops will address topics such as oncology, companion diagnostics, neurological and cardiovascular diseases.
Plenary sessions include: Opening Plenary: Picks and Pans - The Buy-Side View for 2012 Monday, February 13th, 12:00 pm - 12:55 pm
Moderator: Stephen Sands, Vice Chairman of US Investment Banking and Global Co-Head of Healthcare, Lazard Panelists:
Alexander J. Denner, PhD, (former) Managing Director, Icahn Associates Rajiv Kaul, Portfolio Manager, Fidelity Select Biotechnology Portfolio, Fidelity Greg Martinez, Portfolio Manager, Harbor Watch Capital Management LLC Luncheon Plenary: Business Development: Value Drivers Under the Influence - How Licensing and Key Events Affect Valuation Tuesday, February 14th, 12:00 pm - 12:55 pm
Moderator: Ben Bonifant, Senior Vice President and Practice Area Leader, Campbell Alliance Panelists:
Rachel K. King, Chief Executive Officer, GlycoMimetics, Inc. Michael Margolis, RPh, Managing Director, Healthcare Investment Banking, ROTH Capital Partners Barbara Yanni, JD, LLM, CLP, Vice President and Chief Licensing Officer, Merck & Co Closing Plenary: Inside the FDA Tuesday, February 14th, 4:00 pm - 5:00 pm
Moderator: James C. Greenwood, President & CEO, Biotechnology Industry Organization (BIO) Panelists:
Paul J. Hastings, President & CEO, OncoMed Pharmaceuticals, Inc. Jonathan S. Leff, Managing Director, Healthcare, Warburg Pincus, LLC Richard Pops, Chairman & CEO, Alkermes plc Stephen P. Spielberg, MD, PhD, Deputy Commissioner for Medical Products & Tobacco, FDA Business Roundtables include: Business Roundtable: Corporate Strategy Walking the Line - Finding a Happy Medium between Management and Shareholders Monday, February 13th, 9:00 am - 9:55 am
Moderator: Annette Grimaldi, Managing Director, BMO Capital Markets Panelists:
Tillman U. Gerngross PhD, Co-Founder & CEO, Adimab, Inc. Peter Kolchinsky, PhD, Portfolio Manager, RA Capital Management Steven Tregay, PhD, Founder, President & CEO, Forma Therapeutics Steve Worland, PhD, President & CEO (former), Anadys Pharmaceuticals, Inc. Business Roundtable: Finance Healthy Alternatives: Non-Dilutive Financing Mechanisms that Sustain Companies Monday, February 13th, 3:00 pm - 3:55 pm
Moderator: Dean Colucci, President & General Counsel, MLV & Co Panelists:
Luke M. Beshar, CPA, Sr. Vice President & Chief Financial Officer, NPS Pharmaceuticals Inc. John R. Leone, Partner, Healthcare, Paul Capital Ivana Magovčević-Liebisch, PhD, JD. Executive Vice President and Chief Business Officer Russell H. Plumb, MBA, President & Chief Executive Officer, Inhibitex Inc. Business Roundtable: Corporate Development Countdown to Launch - Getting it Right the First Time Tuesday, February 14th, 9:00 am - 9:55 am
Moderator: William Ho, Public Investment Director, New Leaf Venture Partners Panelists:
Pedro Lichtinger, President & CEO, Optimer Pharmaceuticals Timothy P. Walbert, Chairman, President & Chief Executive Officer, Horizon Pharma, Inc. Therapeutic Workshops include: Therapeutic Workshop: Oncology Secrets of Oncology Success - Lessons and Trends in Phase II Clinical Trial Outcomes Monday, February 13th, 10:30 am - 11:25 am
Moderator: Michael G. King, Jr., Managing Director, Rodman & Renshaw, LLC Panelists:
Mohammad Azab, MD, M Sc, MBA, Chief Medical Officer, Astex Pharmaceuticals Inc. Konstantin H. Dragnev, MD, Hematology/Oncology, Dartmouth-Hitchcock Medical Center Michael M. Morrissey, PhD, President & Chief Executive Officer, Exelixis, Inc. Robert F. Ozols, MD, PhD, Senior Vice President, Fox Chase Cancer Center Therapeutic Workshop: Neurology Neurology: "Alz" Well That Ends Well - Settling the Beta - Amyloid Debate Monday, February 13th, 1:30 pm - 2:25 pm
Moderator: Joshua Schimmer, MD, Managing Director, Biotechnology, Leerink Swann, LLC Panelists:
Ted T. Ashburn, MD, PhD, Senior Director, Corporate Development, Genzyme Corp Michael Gold, MS, MD, Vice President, Clinical Development & Chief Medical Officer, Allon Therapeutics Inc. Marc L. Gordon, MD, Chief of Neurology, Associate Professor of Neurology and Psychiatry, Zucker Hillside Hospital, Hofstra North Shore-LIJ School of Medicine Hyoung-Gon Lee, PhD, Assistant Professor, Case Western University Therapeutic Workshop: Diagnostics Drugs Need Friends Too - Companion Diagnostics and Drug Development Tuesday, February 14th, 10:30 am - 11:25 am
Moderator: Steve Brozak, President, WBB Securities LLC Panelists:
Thomas Davis, MD, Senior Vice President & Chief Medical Officer, Celldex Therapeutics, Inc. Joanna C. Horobin, MD, President & CEO, Syndax Pharmaceuticals, Inc. Patrick J. Mahaffy, President and Chief Executive Officer, Clovis Oncology Therapeutic Workshop: Cardiology Shot to the Heart - The Race to Conquer Dyslipidemia / Hypercholesterolemia Tuesday, February 14th, 1:15 pm - 2:10 pm
Moderator: Michael J. Haas, Senior Writer, BioCentury Publications, Inc. Panelists:
Per Bengtsson, MD, PhD, President & CEO, Kara Bio AB Ram Y. Gordon, MD, Clinical Cardiologist, University of Pennsylvania Mark Sumeray, MD, MS, FRCS, Chief Medical Officer, Aegerion Pharmaceuticals, Inc.
To learn more about the BIO CEO & Investor Conference, including registration and program information, please visit here. Registration is complimentary for qualified investors and credential members of the media.
The BIO CEO & Investor Conference is the largest independent investor conference focused solely on publicly-traded biotechnology companies. Investors attend to network with top biotechnology executives, evaluate fresh investment opportunities, attend candid panel discussions and get an overview of the industry and key issues affecting investments.
BIO is pleased to recognize the leadership provided by the BIO CEO & Investor Conference sponsors. The bank sponsors include: BMO Capital Market, Lazard, Leerink Swann, Stifel Nicolaus Weisel, Rodman & Renshaw, LLC and Roth Capital Partners.
|
|
|
|
|
|
| 
